Stock Wars: AstraZeneca Vs. Pfizer
Benzinga’s Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment.
In this week’s installment, we take a look at two pharmaceutical giants at the forefront of the COVID-19 vaccine development:
AstraZeneca plc (NASDAQ:AZN) and
Pfizer Inc. (NYSE:PFE).
The AstraZeneca Experience: AstraZeneca was founded in 1999 through the merger of the Swedish Astra AB, which dated back to 1913, and Britain’s Zeneca Group plc, with the merged company setting up its headquarters in Britain.
During the COVID-19 crisis, AstraZeneca teamed with scientists at Oxford University to create a vaccine to stop the spread of the pandemic. The first doses of the vaccine given to patients outside of clinical tests took place in the U.K. in January, and one month later the World Health Organization issued interim guidance and recommended the vaccine for all adults.
Quem são os donos da AstraZeneca?
rtp.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rtp.pt Daily Mail and Mail on Sunday newspapers.
Quem são os donos da AstraZeneca?
rtp.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rtp.pt Daily Mail and Mail on Sunday newspapers.
by Tyler Durden
Saturday, Apr 03, 2021 - 01:00 PM
Yesterday, regulators in the UK reluctantly acknowledged - or so it seemed, anyway - 25 new cases of rare blood clots linked to the AstraZeneca vaccine. Several of the individuals had died due to the complications. 5 earlier cases had been deemed not serious, but now it appears people are dying in the country that probably has the most to lose if the AstraZeneca jab were to be found defective.
After all, a massive share of Britons who have been inoculated so far were inoculated with the AstraZeneca vaccine,
which was approved for emergency use in the UK late last year, though regulators in the US are only just now starting the process of assessing its efficacy according to the trial data, and its risks.